FDA clears Cervarix for 10- to 25-year-old females

10/18/2009 | WebMD

GlaxoSmithKline has won FDA approval for the use of human papillomavirus vaccine Cervarix in girls ages 10 to 25. The decision is based on clinical trials that demonstrated that Cervarix was 93% effective in protecting patients in the age group from cervical precancers associated with HPV 16 or HPV 18 strains.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY